fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Walgreens Beats Expectations With Strong Pharmacy Sales & Expansion Investments – $WBA $DIA $SPY $INVO

By John F. Heerdink, Jr.

Reportedly, Walgreen Boots Alliance (WBA) quarterly profit exceeded market expectations, driven by stronger-than-anticipated sales in its retail pharmacy business. The increase in prescription drug sales comes as the initial impact of COVID vaccination demand, which initially helped offset low non-COVID prescription volumes during the pandemic, has reversed. Comparable prescription filled (excluding vaccinations) increased by 3.5%, while same-store pharmacy sales rose by 4.9% from the previous year.

The company’s core operations in the US retail pharmacy segment generated $27.6 billion in revenue, surpassing estimated revenue of $26.8 billion by analysts. Walgreens has also been investing in expanding beyond its core business, with recent acquisitions of majority stakes in VillageMD and CareCentrix for $5.5 billion, and Summit Health for $9 billion in January. Despite incurring a one-time opioid-related charge of $306 million and costs related to the acquisition of Summit Health, Walgreens reported earnings of $1.16 per share for the quarter ended in February, exceeding the average analyst estimate of $1.10.


Walgreen Boots Alliance (WBA) is a pharmacy-led, health and well-being enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. To learn more about Walgreen Boots Alliance (WBA) and to continue to track its progress please visit the Vista Partners Walgreens Boots Alliance Page.


Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.





DID YOU KNOW?…

 
On Monday, March 20, INVO Bioscience (NASDAQ: INVO) announced that it has signed binding agreements to acquire a materially transformative acquisition of the Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5 million in revenue and net income of approximately $1.9 million for the trailing 12-month period ended September 30, 2022.
 
 
 
Wisconsin Fertility Institute is led by internationally renowned and well-respected fertility expert, Dr. Elizabeth Pritts, who will continue to serve as the clinic’s lead physician for a minimum period of three years from the closing of the acquisition. Dual-certified in General Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility, Dr. Pritts completed a surgical fellowship in Advanced Gynecologic Laparoscopy and Hysteroscopy. She is also a national leader in the use of robotic surgery for gynecologic disorders. Dr. Pritts served as an assistant professor in reproductive endocrinology and infertility at the University of Wisconsin Medical School, as a clinical fellow at the University of California at San Francisco, and as an instructor at Yale University School of Medicine. She has authored more than 70 articles for scientific publications and has lectured throughout the world on reproduction and fertility.
 
 

Dr. Elizabeth Pritts, M.D., Wisconsin Fertility Institute’s Co-founder

 
 
“I’m excited to be teaming up with INVO as a unique and attractive partner to help advance us to the next phase of our practice. INVO’s commercial strategy and patient focus, along with its public-company platform and the INVOcell technology itself, offers an exciting pathway to build value and increase access to an efficient, effective, affordable, and connected experience in reproductive treatment. Our team looks forward to being an integral part of INVO’s long-term growth and success.” Dr. Elizabeth Pritts, Wisconsin Fertility Institute’s co-founder.
 
 
 
Wisconsin Fertility Institute joins INVO’s expanding list of fertility clinics, including operating clinics in Atlanta (Bloom Fertility), Birmingham (Innovative Fertility Specialists) and Monterrey, Mexico (Positib Fertility), as well as future clinics under development, such as the wholly owned INVO Center in Tampa, Florida that is currently under construction. INVO’s revolutionary medical device, the INVOcell, allows fertilization and early embryo development to occur in vivo with the woman’s body and is also available at a growing list of non-affiliated fertility centers in the United States and around the world.
 
(Read Original Story: Walgreens quarterly profit beats estimates on strong pharmacy performance in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us